Eden Research brings in Aoife Dillon as new head of biology
By Josh White
Date: Friday 10 Jul 2020
(Sharecast News) - Biopesticide and encapsulation technology company Eden Research announced the appointment of Dr Aoife Dillon to the role of head of biology on Friday.
The AIM-traded firm said Dr Dillon was joining Eden from Plant Health Care, where she was technical director for the Europe, Middle East, Africa and Asia geography for the last three years.
She was previously chief technology officer at Exosect - a formulations company focussed on the targeted delivery of biological and synthetic compounds used in agriculture, where she oversaw the granting of four key patents for the company.
At Eden, the board said Dr Dillon would undertake global responsibility for developing its product pipeline from a biology standpoint, working closely with its research and development team team.
It said her appointment followed the opening of the firm's new laboratory, where it would conduct in-house processes for developing and screening new products.
Dr Dillon would be "heavily involved" in assessing the efficacy and safety of new formulations, and running commercial scale trials focused on plant biology for the environment and sustainability.
She would also work with its commercial partners, in order to support their efforts and ultimately grow the list of authorised uses for Eden's product portfolio.
The board said Dr Dillon has "considerable" regulatory affairs experience in plant protection products and biostimulants, as well as experience running coordinated crop trials internationally for more than two decades.
It noted that during her career, she had roles at BASF, Horticultural Development Company and Coillte, and holds a PhD in integrated pest management, a Diploma in project management, and a Master of Science in biological crop protection.
"[Dr Dillon] brings an impressive range of senior executive experience and the ability to engage with and influence key stakeholders in the development and commercialisation of biocontrol products," said chief executive officer Sean Smith.
"Aoife has a track record of driving change, as well as developing and delivering on sustainability standards, which are at the core of Eden's proposition.
"Her presence at our new laboratory facilities will be integral as we ramp up our in-house capabilities to develop our product pipeline."
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN